Description

Halozyme Therapeutics, Inc., a biopharmaceutical technology company, was established in 1998 and is based in San Diego, California. The company's operations span globally, covering markets in the United States, Switzerland, Ireland, Belgium, and Japan. At the heart of Halozyme's offerings is its patented ENHANZE drug delivery technology. This innovative platform leverages rHuPH20, a recombinant human hyaluronidase enzyme, to allow for the subcutaneous administration of various injectable therapies. These include complex biologics like monoclonal antibodies and other therapeutic molecules, as well as smaller chemical compounds and fluids. The company's most prominent product is Hylenex recombinant, which is a specialized formulation of rHuPH20. Hylenex serves multiple purposes: it assists in delivering subcutaneous fluids for hydration, enhances the diffusion and uptake of other injected medications during subcutaneous urography, and improves the clearance of radiopaque agents. Halozyme's portfolio also includes several advanced therapies and pipeline candidates. Notable products either developed with or utilizing their technology include Perjeta; RITUXAN HYCELA and MabThera SC, both indicated for non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC, also for CLL; and HYQVIA, used to treat immunodeficiency disorders. In its development pipeline, Halozyme is working on treatments such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Further investigational assets comprise nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. The company maintains extensive strategic collaborations with a broad spectrum of pharmaceutical and research organizations. These partners include major players like F. Hoffmann-La Roche, Ltd., Baxalta US Inc., Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. Additionally, Halozyme partners with institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited. These alliances focus on developing both small and large molecule therapeutics, particularly for the treatment and prevention of HIV, among other critical health areas.